Safety of coronary stenting with Eptifibatide and ultra-low-dose heparin

被引：5

作者：

Le May, M

Kurdi, M

Labinaz, M

Glover, C

So, D

Ryan, S

Davies, R

机构：

[1] Univ Ottawa, Inst Heart, Ottawa, ON K1Y 4W7, Canada

[2] King Saud Univ, King Khalid Univ Hosp, Riyadh 11472, Saudi Arabia

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2005年 / 95卷 / 05期

关键词：

D O I：

10.1016/j.amjcard.2004.11.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

With the advent of multiple potent antiplatelet and anticoagulation agents in percutaneous coronary intervention (PCI), the risk of bleeding complications has increased. The optimal dose of unfractionated heparin in this setting is unclear. This study was designed to determine the feasibility and safety of PCI with an ultra-low-close weight-adjusted unfractionated heparin regimen (30 IU/kg bolus, maximum 3,000 IU) in combination with aspirin, clopidogrel, and eptifibatide. We enrolled 83 patients who underwent nonemergency PCI of native coronary arteries. At 30 days, all patients were free of the primary clinical outcomes defined as a composite of death, myocardial infarction, or repeat target vessel revascularization, and there were no major bleeding complications. (C)2005 by Excerpta Medica Inc.

引用

页码：630 / 632

页数：3

共 14 条

[1] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[2] THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].

CHESEBRO, JH ;

KNATTERUD, G ;

ROBERTS, R ;

BORER, J ;

COHEN, LS ;

DALEN, J ;

DODGE, HT ;

FRANCIS, CK ;

HILLIS, D ;

LUDBROOK, P ;

MARKIS, JE ;

MUELLER, H ;

PASSAMANI, ER ;

POWERS, ER ;

RAO, AK ;

ROBERTSON, T ;

ROSS, A ;

RYAN, TJ ;

SOBEL, BE ;

WILLERSON, J ;

WILLIAMS, DO ;

ZARET, BL ;

BRAUNWALD, E .

CIRCULATION, 1987, 76 (01) :142-154

[3] A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention [J].

Choussat, R ;

Montalescot, G ;

Collet, JP ;

Vicaut, E ;

Ankri, A ;

Gallois, V ;

Drobinski, G ;

Sotirov, I ;

Thomas, D .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (11) :1943-1950

[4]

Godon P, 2001, ARCH MAL COEUR VAISS, V94, P984

[5] Minimal heparinization in coronary angioplasty - How much heparin is really warranted? [J].

Kaluski, E ;

Krakover, R ;

Cotter, G ;

Hendler, A ;

Zyssman, I ;

Milovanov, O ;

Blatt, A ;

Zimmerman, E ;

Goldstein, E ;

Nahman, V ;

Vered, Z .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (08) :953-956

[6] A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel [J].

Kastrati, A ;

Mehilli, J ;

Schühlen, H ;

Dirschinger, J ;

Dotzer, F ;

ten Berg, JM ;

Neumann, F ;

Bollwein, H ;

Volmer, C ;

Gawaz, M ;

Berger, PB ;

Schomig, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :232-238

[7] Safety of low dose heparin in elective coronary angioplasty [J].

Koch, KT ;

Piek, JJ ;

deWinter, RJ ;

David, GK ;

Mulder, K ;

Tijssen, JGP ;

Lie, KI .

HEART, 1997, 77 (06) :517-522

[8] Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin [J].

Koch, KT ;

Piek, JJ ;

de Winter, RJ ;

Mulder, K ;

Schotborgh, CE ;

Tijssen, JGP ;

Lie, KI .

HEART, 1999, 81 (01) :53-56

[9] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial [J].

Lincoff, AM ;

Bittl, JA ;

Harrington, RA ;

Feit, F ;

Kleiman, NS ;

Jackman, JD ;

Sarembock, IJ ;

Cohen, DJ ;

Spriggs, D ;

Ebrahimi, R ;

Keren, G ;

Carr, J ;

Cohen, EA ;

Betriu, A ;

Desmet, W ;

Kereiakes, DJ ;

Rutsch, W ;

Wilcox, RG ;

de Feyter, PJ ;

Vahanian, A ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07) :853-863

[10]

Tcheng JE, 2000, LANCET, V356, P2037

← 1 2 →